Syneron and Candela to Merge
Syneron Medical will purchase aesthetic laser pioneer Candela Corporation for $65 million, creating a global leader in the medical aesthetic device market.
feature2
Opexa Shares Soar on Multiple Sclerosis Trial Data
Opexa Therapeutics announced that 83 percent of clinical trial patients taking its therapeutic vaccine Tovaxin remained relapse-free for a year.
FDA Grants Luminex 510(k) Clearance for Cystic Fibrosis Test
The xTAG Cystic Fibrosis 39 Kit v2 is intended to be a faster, more convenient way to screen for CF.
Building a Better Anthrax Vaccine
Swine flu may be causing a current panic, but eight years ago, our big concern was anthrax.
Fall Allergy Season Is Upon Us
Ragweed season is under way, bringing with it sneezes, sniffles, and itchy eyes for 36 million Americans.
Sen. Kennedy Death Puts Focus On Brain Cancer
Glioblastoma multiforme (GBM), the aggressive brain tumor that took Sen. Kennedy’s life, is one of the deadliest brain tumors that can occur in both adults and children.
The Key to Stopping Colon Cancer?
Scientists in Switzerland may have found a way to inhibit the growth of colon cancer in humans, says a new study published in EMBO Molecular Medicine.
Another Company Announces Positive Lupus Drug Data
Immunomedics has become the second biopharmaceutical company in recent weeks to announce a successful trial of its lupus drug.
Protalix Granted Fast-Track Review for Gaucher Drug
The U.S. Food and Drug Administration has granted a fast-track review to Protalix BioTherapeutics’ experimental treatment for Gaucher disease.
NeoPharm Tipped As Stock to Watch
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.